N-methyl-tert-butylbenzenesulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-methyl-tert-butylbenzenesulfonamide
• 英文别名: N-(tert-Pentyl)benzenesulfonamide；N-(2-methylbutan-2-yl)benzenesulfonamide
• 化学式: C₁₁H₁₇NO₂S
• mdl: MFCD05660913
• 分子量: 227.327
• InChiKey: REOBTHQZMVAVFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  顺-1,2-二氯乙烯 、 N-methyl-tert-butylbenzenesulfonamide 在 caesium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 18.0h， 以97%的产率得到(Z)-N,N′-(ethene-1,2-diyl)bis(4-(tert-butyl)-N-methylbenzenesulfonamide)
  参考文献：
  名称：

  一种制备1,2-烯二酰胺类化合物的方法

  摘要：

  本发明提供了一种制备1,2‑烯二酰胺类化合物的方法，所述方法的主要步骤是：在碱性条件下，由1,1‑二氯乙烯或顺‑1,2‑二氯乙烯与仲酰胺在非质子有机溶剂中反应，得到目标产物(对称的1,2‑烯二酰胺类化合物)。本发明的方法具有低成本(不需使用催化剂)、条件温和、原料简单易得、应用前景广泛等优点。

  公开号：

  CN112430200A

文献信息

• Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands
  申请人：Cheng Yun-Xing

  公开号：US20100113502A1

  公开（公告）日：2010-05-06

  Compounds of formulae I, or pharmaceutically acceptable salts thereof: wherein R 1 , R 2 and R 3 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  化合物I的公式，或其药学上可接受的盐：其中R1、R2和R3如规范中所定义，以及包括这些化合物的盐和药物组合物已被制备。它们在治疗中很有用，特别是在疼痛管理方面。
• UBIQUITIN LIGASE INHIBITORS
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：EP1651595A2

  公开（公告）日：2006-05-03
• COMPOUNDS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
  申请人：Teleos Therapeutics, LLC

  公开号：US20180161310A1

  公开（公告）日：2018-06-14

  Compounds that inhibit synaptic hyperexcitability, pharmaceutical compositions of these compounds, and methods of using the compounds and pharmaceutical compositions thereof to treat diseases and/or disorders such as epilepsy, neuropathic pain, spinal cord injury spasticity, morphine-induced hyperalgesia, schizophrenia, and autism spectrum disorders are disclosed. In some embodiments, the compounds have the general structure of Formula 1 or Formula 2:
• [EN] UBIQUITIN LIGASE INHIBITORS<br/>[FR] INHIBITEURS DE LIGASE D'UBIQUITINE
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2005007621A2

  公开（公告）日：2005-01-27

  This invention describes compounds useful as ubiquitin ligase inhibitors. The compounds of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also provides for pharmaceutical compositions comprising the compounds described in the invention for the treatment of conditions that require inhibition of ubiquitin ligases. Furthermore, the invention provides for methods of inhibiting ubiquitination in a cell comprising contacting a cell in which inhibition of ubiquitination is desired with a compound according to the invention.